Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/070012external-prioritypatent/WO2014078486A1/en
Application filed by Incyte CorpfiledCriticalIncyte Corp
Publication of PH12019501070A1publicationCriticalpatent/PH12019501070A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
PH12019501070A2012-11-152019-05-14Sustained-release dosage forms of ruxolitinib
PH12019501070A1
(en)
3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES